Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Analysis of Infections and All‐Cause Mortality in Phase II, Phase III, and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

Open access
Cohen, Stanley, Radominski, Sebastião C., Gomez‐Reino, Juan J., Wang, Lisy, Krishnaswami, Sriram, Wood, Susan P., Soma, Koshika, Nduaka, Chudi I., Kwok, Kenneth, Valdez, Hernan, Benda, Birgitta, Riese, Richard · 2014 · Arthritis & Rheumatology

Abstract

Objective: To determine the rate of infection and all‐cause mortality across tofacitinib phase II, phase III, and long‐term extension (LTE) studies in patients with moderately to severely active rheumatoid arthritis (RA). Methods: Pooled data from studies of tofacitinib in patients with RA were analyzed. In these studies, tofacitinib was administered as monotherapy or in combination with methotrexate or other nonbiologic disease‐modifying antirheumatic drugs. The cutoff date for inclusion of data was April 19, 2012. Results: Across phase II, phase III, and LTE studies, 4,789 patients received tofacitinib (8,460 patient‐years of exposure). The overall rate of serious infection was 3.09 events per 100 patient‐years (95% confidence interval [95% CI] 2.73–3.49), and rates were stable over time. A Cox proportional hazards model showed that age, corticosteroid dose, diabetes, and tofacitinib dose were independently linked to the risk of serious infection. Lymphocyte counts of <0.5 × 10 3/mm 3 were rare but were associated with an increased risk of treated and/or serious infection. Overall, all‐cause mortality rates were 0.30 events per 100 patient‐years (95% CI 0.20–0.44). Conclusion: The overall risk of infection (including serious infection) and mortality rates in RA patients treated with tofacitinib appear to be similar to those observed in RA patients treated with biologic agents. The rates of serious infection were stable over time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.38779

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 173

Metadata

Authors
Cohen, S., Radominski, S. C., Gomez‐Reino, J. J., Wang, L., Krishnaswami, S., Wood, S. P., Soma, K., Nduaka, C. I., Kwok, K., Valdez, H., Benda, B., & Riese, R.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2014-10-26
Volume
66
Issue
11
Pages
2924-2937
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W1921689204
Cited by
173
References
1
FWCI
14.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.